Skip to main content
. Author manuscript; available in PMC: 2020 Aug 18.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 Apr 3;19(6):356–364.e3. doi: 10.1016/j.clml.2019.03.022

Table II.

Adverse events at Least Possibly Related to Pembrolizumab that Occurred in at Least 2 Patients in the Safety Population (N=18)

Toxicity Total N (%) Grade N (%)
1 2 3 4 5
Hypothyroidism 2 (11) 1 (6) 1 (6)
Watering eyes 2 (11) 1 (6) 1 (6)
Chills 2 (11) 2 (11)
Edema 2 (11) 2 (11)
Fatigue 2 (11) 2 (11)
Fever 2 (11) 2(11)
Injection reaction 2 (11) 2 (11)
Dyspnea 2 (11) 1 (6) 1 (6)
Pneumonitis 2 (11) 1 (6) 1 (6)
Rash 3 (17) 1 (6) 2 (11)